On July 26th, 2023, Alephoson Biopharmaceuticals Limited hosted a conference and showcased it’s technological innovation and investment potential, with the support from DIBC and the Bank of Jiangsu’s, where it was held at it’s private banking ballroom of the Global Harbor Center, Shanghai. With the theme “A New Horizon in Eye Disease Treatment” , the conference was attended by over 50 participants, including representatives from venture capital firms, such as Qiming Venture Partners, Fuson Capital, Haier Capital, Yonghua capital and ZUIG investment as well as pharmaceutical companies such as Fosun Pharma, China Resources Pharmaceutical, ZHAOKE Ophthalmology and Boan Biotech. The sessions aimed to explore the challenges and the latest developments of eye disease treatments.
Professor Quan Dong Nguyen from Stanford University and Professor Mårten E BRELÉN from The Chinese University of Hong Kong, who are both scientific advisors to Alephoson Biopharmaceuticals, also presented at the conference, discussing the current treatment of Age- Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). They pointed out that there are significant unmet medical needs in current treatments, and innovative formulations urgently need to be developed. They also shared some new treatment ideas and methods.
Professor Gang Wei from Fudan University also presented his research progress to develop innovative ophthalmic formulations and introduced the advantages of using cell-penetrating peptides for ophthalmic drug delivery. Cell-penetrating peptides are molecules that can promote drug entry into cells through the cell membrane and improve drug bioavailability and therapeutic effects. Professor Wei stated that cell-penetrating peptide delivery technology is an important development direction in the field of ophthalmic drug delivery and has great application prospects in the future. His report received extensive attention and discussions among the participants.
Dr. Benjamin LEE, founder & CEO of Alephoson Biopharmaceuticals introduced the technical characteristics and clinical application prospects of their key product, CPB202. Aiming to become a first-in-class drug, CPB202 can effectively treat neovascular age-related macular degeneration for millions of patients without the need for needle injections, thus avoiding the various side effects associated with intravitreal injections. This product has significant clinical value and is expected to become an important breakthrough in the field of ophthalmic treatment.
Alephoson Biopharmaceuticals also introduced its future development plan. The company expects to raise USD $10 million to promote the Investigational New Drug (IND) application process and conduct phase I clinical trials for CPB202. The fund will accelerate the listing process of CPB202 and provide solid support for the company’s future development.
In summary, the “A New Horizon in Eye Disease management” conference provided a platform for industry experts, scholars, and companies to communicate and cooperate, injecting new momentum into the development of China’s ophthalmic treatment field. We believe that with the joint efforts of all parties, more innovative products and technologies will emerge in the future, bringing better treatments and health care to patients.
